BioCentury
ARTICLE | Finance

Making do at Amgen

August 20, 2007 7:00 AM UTC

Investors did not rush to the exits after Amgen Inc.'s announcement that it would restructure last week, as the move was expected. And while some are nervous about where the bottom is for sales of the company's Aranesp and Epogen erythropoiesis-stimulating agents, in general they say the company is making the best of a bad situation.

"Do they do something, or nothing at all" said Kurt von Emster of MPM Capital. "Clearly, they have to do something."...